TG Therapeutics TGTX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's other income (expense)?
- TG Therapeutics (TGTX) reported other income (expense) of -$14.43M in Q1 2026.
- How has TG Therapeutics's other income (expense) changed year-over-year?
- TG Therapeutics's other income (expense) decreased by 357.6% year-over-year, from -$3.15M to -$14.43M.
- What is the long-term trend for TG Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), TG Therapeutics's other income (expense) has grown at a 47.9% compound annual growth rate (CAGR), from -$3.33M to -$15.93M.
- What does other income (expense) mean?
- The net result of income and expenses not related to core business operations.
- How do you interpret other income (expense)?
- Positive values indicate supplemental income, while negative values represent non-operating costs that drag down overall profitability.
- How does other income (expense) compare across companies?
- Highly variable across companies depending on their investment portfolios and non-core asset holdings.